Abstract：
Acute kidney injury (AKI) is the most common and critical complication in patients with acute myocardial infarction (AMI). This study aims to evaluate the significance of elevated soluble interleukin 2 receptor (sIL-2R) levels in predicting AKI and mortality.
A total of 446 patients with AMI were enrolled between January 2020 and July 2022, including 58 patients with AKI and 388 without AKI. The sIL-2R levels were measured using a commercially available chemiluminescence enzyme immunoassay. Logistic regression analysis was used to examine the risk factors for AKI. Discrimination was assessed based on the area under the receiver operating characteristic curve. The model was internally validated using 10-fold cross-validation.
During hospitalization, 13% of patients developed AKI following AMI, with higher sIL-2R levels (0.61 ± 0.27 U/L vs. 0.42 ± 0.19 U/L, p = 0.003) and in-hospital all-cause mortality (12.1% vs. 2.6%, P < 0.001). The sIL-2R levels emerged as an independent risk factor for both AKI (OR = 5.08, 95% CI (1.04-24.84, p < 0.045) and in-hospital all-cause mortality (OR = 73.57,95% CI 10.24-528.41, p < 0.001) in AMI patients. The sIL-2R levels were found to be useful biomarkers in prediction of AKI and in-hospital all-cause mortality in patients with AMI (AUC: 0.771 and 0.894, respectively). The respective cutoff values for sIL-2R levels in predicting AKI and in-hospital all-cause mortality were determined to be 0.423 U/L and 0.615 U/L.
The level of sIL-2R was an independent risk factor and predictor for both AKI and in-hospital all-cause mortality in patients with AMI. These findings highlight the potential of sIL-2R as a valuable tool for identifying high-risk patients regarding AKI and in-hospital mortality.
A total of 446 patients with AMI were enrolled between January 2020 and July 2022, including 58 patients with AKI and 388 without AKI. The sIL-2R levels were measured using a commercially available chemiluminescence enzyme immunoassay. Logistic regression analysis was used to examine the risk factors for AKI. Discrimination was assessed based on the area under the receiver operating characteristic curve. The model was internally validated using 10-fold cross-validation.
During hospitalization, 13% of patients developed AKI following AMI, with higher sIL-2R levels (0.61 ± 0.27 U/L vs. 0.42 ± 0.19 U/L, p = 0.003) and in-hospital all-cause mortality (12.1% vs. 2.6%, P < 0.001). The sIL-2R levels emerged as an independent risk factor for both AKI (OR = 5.08, 95% CI (1.04-24.84, p < 0.045) and in-hospital all-cause mortality (OR = 73.57,95% CI 10.24-528.41, p < 0.001) in AMI patients. The sIL-2R levels were found to be useful biomarkers in prediction of AKI and in-hospital all-cause mortality in patients with AMI (AUC: 0.771 and 0.894, respectively). The respective cutoff values for sIL-2R levels in predicting AKI and in-hospital all-cause mortality were determined to be 0.423 U/L and 0.615 U/L.
The level of sIL-2R was an independent risk factor and predictor for both AKI and in-hospital all-cause mortality in patients with AMI. These findings highlight the potential of sIL-2R as a valuable tool for identifying high-risk patients regarding AKI and in-hospital mortality.
摘要：
背景：急性肾损伤（AKI）是急性心肌梗死（AMI）患者最常见和最严重的并发症。这项研究旨在评估升高的可溶性白介素2受体（sIL-2R）水平在预测AKI和死亡率中的意义。
方法：2020年1月至2022年7月共纳入446例AMI患者，包括58例AKI患者和388例无AKI患者。使用市售化学发光酶免疫测定法测量sIL-2R水平。采用Logistic回归分析探讨AKI的危险因素。基于受试者工作特征曲线下的面积评估辨别。该模型使用10倍交叉验证进行内部验证。
结果：住院期间，13%的患者在AMI后发生AKI，sIL-2R水平较高（0.61±0.27U/Lvs.0.42±0.19U/L,p=0.003）和住院全因死亡率（12.1%与2.6%,P<0.001)。sIL-2R水平是AMI患者AKI（OR=5.08，95％CI（1.04-24.84，p<0.045）和住院全因死亡率（OR=73.57，95％CI10.24-528.41，p<0.001）的独立危险因素。发现sIL-2R水平是预测AMI患者AKI和院内全因死亡率的有用生物标志物(AUC:分别为0.771和0.894)。sIL-2R水平在预测AKI和院内全因死亡率中的各自临界值分别为0.423U/L和0.615U/L。
结论：sIL-2R水平是AMI患者AKI和院内全因死亡的独立危险因素和预测因子。这些发现强调了sIL-2R作为识别AKI高危患者和院内死亡率的有价值的工具的潜力。
方法：2020年1月至2022年7月共纳入446例AMI患者，包括58例AKI患者和388例无AKI患者。使用市售化学发光酶免疫测定法测量sIL-2R水平。采用Logistic回归分析探讨AKI的危险因素。基于受试者工作特征曲线下的面积评估辨别。该模型使用10倍交叉验证进行内部验证。
结果：住院期间，13%的患者在AMI后发生AKI，sIL-2R水平较高（0.61±0.27U/Lvs.0.42±0.19U/L,p=0.003）和住院全因死亡率（12.1%与2.6%,P<0.001)。sIL-2R水平是AMI患者AKI（OR=5.08，95％CI（1.04-24.84，p<0.045）和住院全因死亡率（OR=73.57，95％CI10.24-528.41，p<0.001）的独立危险因素。发现sIL-2R水平是预测AMI患者AKI和院内全因死亡率的有用生物标志物(AUC:分别为0.771和0.894)。sIL-2R水平在预测AKI和院内全因死亡率中的各自临界值分别为0.423U/L和0.615U/L。
结论：sIL-2R水平是AMI患者AKI和院内全因死亡的独立危险因素和预测因子。这些发现强调了sIL-2R作为识别AKI高危患者和院内死亡率的有价值的工具的潜力。
